Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT05357911 Completed - Solid Tumor Clinical Trials

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

Start date: July 13, 2021
Phase: Phase 1
Study type: Interventional

AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). (n=16)

NCT ID: NCT05357820 Completed - Solid Tumor Clinical Trials

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

Start date: July 19, 2021
Phase: Phase 1
Study type: Interventional

AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)(n=56)

NCT ID: NCT05336279 Completed - Solid Tumor Clinical Trials

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Start date: May 11, 2022
Phase: Phase 1
Study type: Interventional

The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 28 healthy subjects. Subjects will receive famitinib malate on Day1 and Day13.

NCT ID: NCT05248074 Completed - Solid Tumor Clinical Trials

To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers

Start date: January 4, 2022
Phase: Phase 1
Study type: Interventional

This randomized open-label, two-way crossover study is designed to evaluate the safety and pharmacokinetic characteristics of ABN401, and the effect of high-fat meal on the pharmacokinetic profiles of ABN401 and its metabolites in healthy adult volunteers.

NCT ID: NCT05230290 Completed - Solid Tumor Clinical Trials

Clinical Study of KD6001 in Advanced Solid Tumours

Start date: September 10, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.

NCT ID: NCT05190263 Completed - Solid Tumor Clinical Trials

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma

QA Anemia
Start date: October 25, 2021
Phase:
Study type: Observational

The aim of the study is to analyze the implementation of the 2018 updated ESMO Guideline in patients with tumor diseases as well as the corre-sponding recommendations of the Onkopedia Guideline and the S3 Guide-line Supportive Therapy in routine clinical practice in Germany. To this end, a nationwide, representative, retrospective patient documen-tation will be conducted to observe the current practice of anemia man-agement in hospitals and among office-based physicians.

NCT ID: NCT05173792 Completed - Solid Tumor Clinical Trials

Study of AK119 in Subjects With Advanced Solid Tumors

Start date: December 22, 2021
Phase: Phase 1
Study type: Interventional

This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.

NCT ID: NCT05134636 Completed - Cancer Clinical Trials

Text-based Intervention to Minimize the Time Burden of Routine Cancer Care

TIME
Start date: December 6, 2021
Phase: N/A
Study type: Interventional

The primary objective is to test whether a text-based e-triage can safely minimize the time associated with routine cancer care by identifying patients who can proceed directly to their immunotherapy infusion without a preceding in-person office assessment.

NCT ID: NCT05126927 Completed - Solid Tumor Clinical Trials

A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

Start date: November 2, 2021
Phase: Early Phase 1
Study type: Interventional

Primary objective To investigate the safety and tolerability profile of 68Ga- NODAGA-SNA006 in patients with solid tumors; To investigate the radiation absorbed dose characteristics of 68Ga-NODAGA-SNA006 in patients with solid tumors; To investigate the distribution profile of 68Ga-NODAGA-SNA006 in patients with solid tumors. Secondary objectives To investigate the optimal administration dose and radiation safety profile of 68Ga-NODAGA-SNA006; To investigate the PET imaging characteristics and high-quality imaging time window of 68Ga-NODAGA-SNA006 in patients with solid tumors; To explore the correlation between PET imaging characteristics of 68Ga-NODAGA-SNA006 binding to CD8 and histological CD8 expression characteristics; To explore peripheral blood T lymphocyte differentiation (CD8, CD4, CD3, etc.) in patients with solid tumors.

NCT ID: NCT05119998 Completed - Solid Tumor Clinical Trials

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Start date: February 8, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of IBI325 in patients with advanced solid tumors